Michał Mielnik

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +13

ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma

Szymon Zmorzyński, Aneta Szudy‐Szczyrek, Sylwia Popek-Marciniec et al. · Frontiers in Oncology · 2019 · 36 citations · Full text

Medicine, Genetics, Hematology +15

Serum brain‐derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients

Aneta Szudy‐Szczyrek, Radosław Mlak, Magdalena Bury‐Kamińska et al. · British Journal of Haematology · 2020 · 24 citations · Full text

Medicine, Neurology, Oncology +13

Male gender and age range 20–29 years are the most important non-modifiable risk factors for recurrence after primary post-traumatic shoulder dislocation

Karol Szyluk, Andrzej Jasiński, Paweł Niemiec et al. · Knee Surgery Sports Traumatology Arthroscopy · 2018 · 23 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +12

Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen

Aneta Szudy‐Szczyrek, Radosław Mlak, Michał Mielnik et al. · Annals of Hematology · 2020 · 23 citations · Full text

Medicine, Hematology, Oncology +15